Your browser doesn't support javascript.
Anti-inflammatory and immune therapy in severe coronavirus disease 2019 (COVID-19) patients: An update.
Zhang, Wen; Qin, Chenman; Fei, Yunyun; Shen, Min; Zhou, Yangzhong; Zhang, Yan; Zeng, Xiaofeng; Zhang, Shuyang.
  • Zhang W; Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Beijing 100730, China.
  • Qin C; Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Beijing 100730, China; Department of Rheumatology of Immunolog
  • Fei Y; Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Beijing 100730, China.
  • Shen M; Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Beijing 100730, China.
  • Zhou Y; Department of internal medicine, Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College Hospital, Beijing 100730, China.
  • Zhang Y; Department of Hematology, Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College Hospital, Beijing 100730, China.
  • Zeng X; Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Beijing 100730, China. Electronic address: xiaofeng.zeng@cstar
  • Zhang S; Department of Cardiology, Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College Hospital, State Key Laboratory of Complex Severe and Rare Diseases, Beijing 100730, China. Electronic address: zhangshuyang2018@126.com.
Clin Immunol ; 239: 109022, 2022 06.
Article in English | MEDLINE | ID: covidwho-1803761
ABSTRACT
In March 2020, when coronavirus disease 2019 (COVID-19) was just beginning to spread around the world, we presented the potential benefits and controversies of anti-inflammatory therapy in COVID-19 patients based on the limited experience and proposed some types of anti-inflammatory drugs with potential therapeutic value, while without evidence-based data. In the past one more year, many clinical trials or real-world studies have been performed, either confirm or deny the efficacy of certain anti-inflammatory drugs in the treatment of COVID-19. In this review we summarize the progress of anti-inflammatory and immune therapy in COVID-19, including glucocorticoids, IL-6 antagonist, IL-1 inhibitor, kinase inhibitors, non-steroidal anti-inflammatory drugs and chloroquine/hydroxychloroquine.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment Type of study: Prognostic study Limits: Humans Language: English Journal: Clin Immunol Journal subject: Allergy and Immunology Year: 2022 Document Type: Article Affiliation country: J.clim.2022.109022

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment Type of study: Prognostic study Limits: Humans Language: English Journal: Clin Immunol Journal subject: Allergy and Immunology Year: 2022 Document Type: Article Affiliation country: J.clim.2022.109022